Class information for:
Level 2: IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
151 22214 45.6 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 3)


ID, lev.
above		 Publications Label for level above
18 119602 JOURNAL OF IMMUNOLOGY//IMMUNOL//DENDRITIC CELLS

Classes in level below (level 1)


ID, lev. below Publications Label for level below
640 3135 DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE
1433 2567 CANCER TESTIS ANTIGEN//CANCER TESTIS ANTIGENS//NY ESO 1
3572 1879 DNA VACCINE//DNA VACCINES//DNA IMMUNIZATION
3837 1824 FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL
4142 1764 CHIMERIC ANTIGEN RECEPTOR//ADOPTIVE CELL THERAPY//CHIMERIC IMMUNE RECEPTOR
7665 1262 BRAIN TUMOR PROGRAM//GLIOMA IMMUNOTHER Y GRP//GL261
7789 1248 ANTIGEN PROCESSING MACHINERY//BIOQUIM BIOL MOL INMUNOL 3//HLA CLASS I
9065 1124 MYELOID DERIVED SUPPRESSOR CELLS//MDSC//MYELOID DERIVED SUPPRESSOR CELL
9858 1050 ADV CELL MOL THER Y//SHUNDE PEOPLES HOSP//TUMOR VACCINE
10495 992 TUMOR INFILTRATING LYMPHOCYTES//ADOPTIVE IMMUNOTHERAPY//AUTOLYMPHOCYTE THERAPY
12907 810 IDIOTYPE//IDIOTYPE VACCINATION//CELL THER Y AREA
16110 605 5T4//TUMOR IMMUNOL BIOL//5T4 ONCOFETAL ANTIGEN
16129 604 PRAME//LEUKEMIA ASSOCIATED ANTIGENS//UNIT 900
16599 580 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
21115 372 VIRAL ONCOLYSATE//CELLULAR IMMUNOL D010//MTH 68 H
21929 343 CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN
22281 330 CYTOKINE INDUCED KILLER CELLS//CIK CELLS//CYTOKINE INDUCED KILLER CELL
22646 318 RECOMBINANT VACCINE GRP//ABSCOPAL EFFECT//IMMUNOGENIC TUMOR CELL DEATH
23068 303 CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION
23240 298 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
23594 286 BELAGENPUMATUCEL L//SRL172//PA MSHA
23992 274 UNITA OPERAT ASSISTENZIALE GINECOL ONCOL//CD1A//CDLA
30701 134 MRNA DELIVERY//MRNA TRANSFECTION//RIBOL
32165 112 ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 IMMUNOTHERAPY Author keyword 532 20% 11% 2346
2 DENDRITIC CELLS Author keyword 329 19% 7% 1584
3 CANCER IMMUNOLOGY IMMUNOTHERAPY Journal 267 24% 4% 985
4 CYTOKINE INDUCED KILLER CELLS Author keyword 223 89% 0% 100
5 JOURNAL OF IMMUNOTHERAPY Journal 222 34% 2% 543
6 CANCER TESTIS ANTIGEN Author keyword 208 76% 1% 148
7 MYELOID DERIVED SUPPRESSOR CELLS Author keyword 201 62% 1% 210
8 CANCER VACCINE Author keyword 179 43% 1% 314
9 CANCER TESTIS ANTIGENS Author keyword 172 77% 1% 116
10 TUMOR INFILTRATING LYMPHOCYTES Author keyword 168 48% 1% 256

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 IMMUNOTHERAPY 532 20% 11% 2346 Search IMMUNOTHERAPY Search IMMUNOTHERAPY
2 DENDRITIC CELLS 329 19% 7% 1584 Search DENDRITIC+CELLS Search DENDRITIC+CELLS
3 CYTOKINE INDUCED KILLER CELLS 223 89% 0% 100 Search CYTOKINE+INDUCED+KILLER+CELLS Search CYTOKINE+INDUCED+KILLER+CELLS
4 CANCER TESTIS ANTIGEN 208 76% 1% 148 Search CANCER+TESTIS+ANTIGEN Search CANCER+TESTIS+ANTIGEN
5 MYELOID DERIVED SUPPRESSOR CELLS 201 62% 1% 210 Search MYELOID+DERIVED+SUPPRESSOR+CELLS Search MYELOID+DERIVED+SUPPRESSOR+CELLS
6 CANCER VACCINE 179 43% 1% 314 Search CANCER+VACCINE Search CANCER+VACCINE
7 CANCER TESTIS ANTIGENS 172 77% 1% 116 Search CANCER+TESTIS+ANTIGENS Search CANCER+TESTIS+ANTIGENS
8 TUMOR INFILTRATING LYMPHOCYTES 168 48% 1% 256 Search TUMOR+INFILTRATING+LYMPHOCYTES Search TUMOR+INFILTRATING+LYMPHOCYTES
9 NY ESO 1 158 78% 0% 105 Search NY+ESO+1 Search NY+ESO+1
10 DENDRITIC CELL 158 20% 3% 693 Search DENDRITIC+CELL Search DENDRITIC+CELL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 TUMOR INFILTRATING LYMPHOCYTES 754 44% 6% 1296
2 ANTITUMOR IMMUNITY 594 36% 6% 1335
3 IMMUNOTHERAPY 577 21% 11% 2514
4 METASTATIC MELANOMA 543 28% 7% 1647
5 CYTOLYTIC T LYMPHOCYTES 535 65% 2% 510
6 CYTOTOXIC T LYMPHOCYTES 471 28% 6% 1419
7 INFILTRATING LYMPHOCYTES 448 50% 3% 640
8 ADOPTIVE IMMUNOTHERAPY 414 39% 4% 844
9 CANCER TESTIS ANTIGENS 404 75% 1% 290
10 MELANOMA PATIENTS 324 44% 2% 550

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER IMMUNOLOGY IMMUNOTHERAPY 267 24% 4% 985
2 JOURNAL OF IMMUNOTHERAPY 222 34% 2% 543
3 ONCOIMMUNOLOGY 69 32% 1% 176
4 CANCER IMMUNOLOGY RESEARCH 26 29% 0% 78
5 CANCER GENE THERAPY 26 12% 1% 212
6 IMMUNOTHERAPY 21 18% 0% 104
7 CYTOKINES CELLULAR & MOLECULAR THERAPY 3 14% 0% 17
8 CYTOKINES AND MOLECULAR THERAPY 1 11% 0% 6

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Myeloid-derived suppressor cells as regulators of the immune system 2009 1561 130 69%
Dendritic cells and the control of immunity 1998 9008 97 45%
Coordinated regulation of myeloid cells by tumours 2012 501 197 56%
Adoptive cell transfer as personalized immunotherapy for human cancer 2015 13 89 79%
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 2015 14 42 67%
Neoantigens in cancer immunotherapy 2015 15 49 61%
Adoptive immunotherapy for cancer: harnessing the T cell response 2012 315 149 72%
Antibody-modified T cells: CARs take the front seat for hematologic malignancies 2014 72 69 74%
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion 2011 762 61 44%
Immunobiology of dendritic cells 2000 4010 276 34%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SURG BRANCH 135 33% 1.5% 333
2 NEW YORK BRANCH 107 54% 0.6% 139
3 TUMOR IMMUNOL BIOL 72 36% 0.7% 161
4 CANC VACCINE DEV 69 75% 0.2% 50
5 CELLULAR GENET UNIT 54 53% 0.3% 70
6 CANC VACCINE DEV PROGRAM 41 90% 0.1% 18
7 CANC IMMUNOL IMMUNOTHER Y 41 58% 0.2% 47
8 LUDWIG CANC 37 10% 1.6% 348
9 CLIN ONCOIMMUNOL 33 45% 0.2% 55
10 INNOVAT CANC THER Y 32 28% 0.4% 96

Related classes at same level (level 2)


Rank Relatedness score Related classes
1 0.0000019390 ORAL TOLERANCE//DC SIGN//DENDRITIC CELLS
2 0.0000018969 TUMOR DORMANCY//DORN VA MED//CONCOMITANT RESISTANCE
3 0.0000018825 FOXP3//CTLA 4//REGULATORY T CELLS
4 0.0000014808 P15E//IMMUNE SUPPRESSOR CELLS//IRX 2
5 0.0000013722 INTERLEUKIN 2//GRANZYME B//PERFORIN
6 0.0000011418 ONCOLYTIC VIRUS//VIROTHERAPY//CYTOSINE DEAMINASE
7 0.0000009912 HLA B8 DR3//INTERDISCIPLINARY STUDIES SECT//AH 81
8 0.0000009559 HLA G//KIR//NKG2D
9 0.0000009026 INVARIANT CHAIN//CIITA//HLA DM
10 0.0000008896 ANKYLOSING SPONDYLITIS//HLA B27//SPONDYLOARTHRITIS